Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

---

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., TUĞLULAR A. T., ARSLAN Ö., GÖKER A. H., ...More

17th International Myeloma Workshop, 12 - 15 September 2019, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• Karadeniz Technical University Affiliated: Yes